Effects of mu, kappa or delta opioids administered by pellet or pump on oral Salmonella infection and gastrointestinal transit

European Journal of Pharmacology
Pu FengT K Eisenstein

Abstract

Our laboratory has shown previously that subcutaneously implanted, slow-release morphine pellets markedly enhanced susceptibility to oral infection with Salmonella typhimurium. Further, morphine, kappa and delta opioid receptor agonists infused via osmotic minipumps were immunosuppressive. The present study compared morphine pellets to morphine pumps and also examined the differential effects of morphine versus U50,488H (kappa agonist), deltorphin II (delta2 agonist), and (D-Pen2, D-Pen5)-enkephalin (DPDPE, delta1 agonist), administered via Alzet minipumps, on oral Salmonella infection and on gastrointestinal transit. The results show that all morphine-pelleted mice (26/26) had a marked increase in Salmonella burden in the Peyer's Patches, mesenteric lymph nodes and spleen. In comparison, only 8/20 mice receiving morphine by minipump at doses ranging from 1 to 25 mg/kg/day had any culturable Salmonella in their organs and the number of bacteria was very low. The level of Salmonella colonization correlated with blood morphine levels and gut transit measured using an intragastric charcoal meal. Morphine pellets inhibited gut transit by 38%, while mice receiving morphine by minipump at doses of 1 to 25 mg/kg/day showed only a dose...Continue Reading

References

Mar 1, 1976·Pharmacology, Biochemistry, and Behavior·C CerlettiM W Alder
Jan 1, 1992·Immunopharmacology and Immunotoxicology·J L BussiereT K Eisenstein
Jan 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·D D TaubT J Rogers
Jan 27, 1988·European Journal of Pharmacology·P S PortogheseA E Takemori
Jan 1, 1988·Life Sciences·T F BurksF Porreca
Oct 5, 1987·Life Sciences·H U BryantJ W Holaday
May 1, 1974·The Journal of Experimental Medicine·P B Carter, F M Collins
Jul 1, 1967·Annals of Internal Medicine·D B LouriaJ Rose
Oct 1, 1966·The Journal of Experimental Medicine·G B MackanessF M Collins
Oct 1, 1983·The Journal of Infectious Diseases·E TubaroC Santiangeli
Feb 1, 1993·Transplantation Proceedings·K ArakawaH Nagase
Jan 1, 1996·Pharmacology & Therapeutics·A De Luca, I M Coupar
Jul 1, 1997·The Journal of Infectious Diseases·M E HilburgerT K Eisenstein
May 29, 1998·Brain Research. Molecular Brain Research·S RoyH H Loh
Aug 8, 1998·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·I Mancini, E Bruera
Oct 31, 1998·Brain Research. Molecular Brain Research·S RoyH H Loh
May 6, 1999·Journal of Neuroimmunology·S RoyR A Barke
Apr 14, 2000·The Journal of Infectious Diseases·A S MacFarlaneT K Eisenstein
Mar 14, 2001·Drug and Alcohol Dependence·L McCarthyT J Rogers
Dec 26, 2001·The Journal of Pharmacology and Experimental Therapeutics·Richard A Houghtling, Barbara M Bayer
Feb 28, 2002·The Journal of Pharmacology and Experimental Therapeutics·DeWayne Townsend, David R Brown
Apr 15, 2003·Clinical Microbiology Reviews·Herman FriedmanThomas W Klein
Jun 5, 2003·Biochemical Pharmacology·Gang WeiChun Su Yuan
Mar 17, 2004·Journal of Neuroimmunology·Frank M OcasioSulie L Chang
Aug 1, 1950·The American Journal of Medicine·H H HUSSEY, S KATZ
Jan 18, 2005·Science·Jan Hendrik NiessHans-Christian Reinecker

❮ Previous
Next ❯

Citations

Jul 27, 2011·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Sabita RoyRoderick A Barke
Jul 15, 2011·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Xu WangWen-Zhe Ho
Aug 10, 2011·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Jessica M BreslowToby K Eisenstein
Jul 22, 2015·Expert Opinion on Drug Discovery·Pamela J Hornby
Oct 24, 2007·Peptides·Richard J Bodnar
Nov 23, 2007·FEMS Immunology and Medical Microbiology·David R Brown, Lisa D Price
Jul 30, 2014·Frontiers in Cellular Neuroscience·Karim Nagi, Graciela Pineyro
Mar 21, 2007·PLoS Pathogens·Olga ZaborinaJohn C Alverdy
Jun 28, 2016·Pharmacological Reviews·Louis GendronGraciela Pineyro
Jun 22, 2018·American Journal of Physiology. Gastrointestinal and Liver Physiology·Jesse J DiCelloDaniel P Poole
Oct 9, 2019·The Journal of Pharmacology and Experimental Therapeutics·Alexandra E ConibearEamonn Kelly
Apr 13, 2020·Journal of Cellular and Molecular Medicine·Hanieh Bagheri TudashkiGraciela Pineyro
Jan 11, 2020·Frontiers in Immunology·Toby K Eisenstein
May 28, 2020·Proceedings of the National Academy of Sciences of the United States of America·Jade DegrandmaisonLouis Gendron
Jan 5, 2021·Molecular Biology Reports·Naser-Aldin LashgariAmir Hossein Abdolghaffari
Sep 25, 2021·Journal of Neuroscience Research·Jade DegrandmaisonLouis Gendron

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.